Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in C:\inetpub\wwwroot\technology_detail.php on line 331
 Technology Detail


The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Peptides for Highly Efficient Cancer Immunotherapy


Stanford Reference:

03-078


Abstract


This simple, patented vaccination strategy is designed to improve cancer immunotherapy by producing a maximally effective T cell response in patients. The approach uses both a native agonist peptide and an analog peptide to elicit high recognition efficiency (RE) T-cells that are truly cytolytic for a target cell. This is an advantage over standard vaccination methods (with high doses of agonist peptides only) which produce predominantly ineffective, low RE T-cells.

Applications


  • Cancer immunotherapy - activate cytolytic T cells for therapeutic and prophylactic vaccines.

Advantages


  • High efficiency vaccination - holds the potential to dramatically improve the clinical efficacy of therapeutic as well as preventive vaccination.

Publications



Related Web Links



Innovators & Portfolio


  • Peter Lee   
  • Tor Stuge   

Patent Status



Date Released

 9/25/2014
 

Licensing Contact


Ximena Ares, Licensing Associate
650-724-0960 (Direct)
Login to Request Information

[-] Map/Timeline

92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-184 Monoclonal Antibody to Human CD81

more technologies »

Related Keywords


immunotherapy   tumorreactive T- cells   cancer immunotherapy   cancer vaccine   anti-tumor   therapeutic: immunotherapy   t cell therapy   T cell   peptides   oncolytic immunotherapy   tumor immunology   tumor vaccine   
 

   

  

Also of Interest...
92-045 Novel Endothelial Adhesion Molecule for Monocytes: L11-CD43
92-146 Achieving B-Cell Lymphoma Growth Modulation and Enhanced Tumor Resistance Using Idiotype/Cytokine Conjugates
97-184 Monoclonal Antibody to Human CD81

Recently Viewed...
S03-078 Peptides for Highly Efficient Cancer Immunotherapy